In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Yuyong Zhou,Kerry Gilmore,Santseharay Ramirez,Eva Settels,Karen A. Gammeltoft,Long V. Pham,Ulrik Fahnøe,Shan Feng,Anna Offersgaard,Jakob Trimpert,Jens Bukh,Klaus Osterrieder,Judith M. Gottwein,Peter H. Seeberger
DOI: https://doi.org/10.1038/s41598-021-93361-y
IF: 4.6
2021-07-16
Scientific Reports
Abstract:Abstract Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration–response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC 50 ) in different cell types: 7–12 μg/mL), followed by artemether (53–98 μg/mL), A. annua extracts (83–260 μg/mL) and artemisinin (151 to at least 208 μg/mL). The selectivity indices (SI), calculated based on treatment and cell viability assays, were mostly below 10 (range 2 to 54), suggesting a small therapeutic window. Time-of-addition experiments in A549-hACE2 cells revealed that artesunate targeted SARS-CoV-2 at the post-entry level. Peak plasma concentrations of artesunate exceeding EC 50 values can be achieved. Clinical studies are required to further evaluate the utility of these compounds as COVID-19 treatment.
multidisciplinary sciences
What problem does this paper attempt to address?